Novavax, Inc. (NASDAQ:NVAX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.

Recs

1
Player Avatar zzlangerhans (99.77) Submitted: 1/10/2013 6:21:48 PM : Outperform Start Price: $1.96 NVAX Score: +22.32

I recently exited an underperform visit on Novavax and was gearing up to red thumb them again, having grown disgusted with an apparently neverending series of phase I trials of various vaccines. However, after witnessing first hand the incredible volume of influenza cases in the emergency room in just the first month of flu season I decided to take a short-term flyer on the stock. I don't really expect stocks like Novavax or Sinovac or Inovio to gain any material benefit from an influenza epidemic, but the effect of influenza hype on these stocks cannot be denied. Even Biocryst seems to be rising and they've all but terminated development of their influenza drug.

By the way, if you haven't been vaccinated yet I believe there is still time. I got vaccinated for just the second time this year (H1N1 epidemic was the first time) but after seeing how many healthy people are being hospitalized this year I'll never put myself or my family at risk again by going unvaccinated.

Member Avatar OklaBoston (67.62) Submitted: 3/8/2013 11:45:05 AM
Recs: 0

No less than 6 brokerages have initiated coverage of this stock since November. That could wellaccount for this trading on high volume lately, but the fundamentals don't justify paying 4 times book for it.

I'm still too chart-oriented to enter an "Underperform" here while the current uptrend lasts, but when it starts makin 20 week lows I might.

Featured Broker Partners


Advertisement